Cytomegalovirus immunisation
Not recruitingEfficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40
Efficacy, Safety, and Immunogenicity of mRNA-1647 Vaccine in Preventing Primary Cytomegalovirus Infection in CMV-Seronegative Females Aged 16-40
- Disease:Cytomegalovirus immunisation
- Substances:Sodium Chloride
Belgium- Participants:0–17 years · 18–64 years · Healthy volunteers
- Substances:Sodium Chloride
- Sponsor:Moderna Therapeutics Inc.











